Table 2 Comparison of MIS-C patients in the IVIG + anakinra group presenting with or without CV shock

Patients (n, %)

12, 38%

20, 63%

N/A

Medications

Inflammatory steroids (n, %)

0, 0%

3, 15%

0.27

Stress hydrocortisone (n, %)

0, 0%

6, 30%

0.06

Anakinra treatment characteristics

Adjunct therapy (n, %)

0, 0%

20, 100%

N/A

First-line rescue therapy (n, %)

12, 100%

0, 0%

N/A

Starting dose, mg/kg/day [Q1, Q3]

7.7 [4.5, 8.0]

7.9 [7.7, 9.9]

0.09

Initiation, hospitalization day [Q1, Q3]

2.0 [2.0, 4.8]

2.0 [1.0, 3.0]

0.11

Max dose, mg/kg/day [Q1, Q3]

8.0 [4.5, 9.2]

9.8 [8.1, 10.0]

0.003

Max dose, mg/dose [Q1, Q3]

41 [30, 94]

55 [46, 100]

0.21

Treatment duration, days [Q1, Q3]

7.1 [4.6, 8.8]

10.6 [9.7, 13.3]

0.002